Evista sales were $263.2 million in the third quarter, a 2 percent increase compared with the third quarter of 2006. U.S. sales of Evista increased 4 percent, to $169.5 million, driven by higher prices. Sales outside the U.S. decreased 1 percent, to $93.7 million.
Cialis sales for the third quarter were $311.4 million. On a pro forma basis, worldwide sales of Cialis grew 27 percent compared with third-quarter 2006, reflecting both strong demand and increased prices in the U.S. and internationally. U.S. sales of Cialis were $116.6 million in the third quarter, a 22 percent increase compared with the third quarter of 2006. Sales of Cialis outside the U.S. increased 30 percent to $194.8 million. Prior to the acquisition of ICOS on January 29, 2007, Cialis sales in Lilly territories were reported in Lilly's revenue, while Lilly's 50 percent share of the joint- venture territory sales, net of expenses, was reported in Lilly's other income. After the acquisition of ICOS, all Cialis sales are reported in Lilly's revenue.
Worldwide Humulin sales increased 6 percent in the third quarter, to $243.3 million. U.S. sales declined 6 percent to $90.8 million due to lower demand, partially offset by higher prices. Sales outside the U.S. increased 14 percent to $152.5 million, driven primarily by increased volume and the favorable impact of foreign exchange rates, offset in part by declining prices.
For the third quarter of 2007, Alimta generated sales of $215.0 million, an increase of 37 percent compared with the third quarter of 2006. U.S. sales of Alimta increased 23 percent, to $110.8 million, due primarily to increased demand, while sales outside the U.S. increased 55 percent, to $104.2 million, due primarily to increased demand.
|SOURCE Eli Lilly and Company|
Copyright©2007 PR Newswire.
All rights reserved